Please note. Investigational: not approved by the FDA. Information is for clinical and research awareness only. Not a recommendation to use.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Sovateltide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A highly selective peptide agonist of the endothelin-B receptor. Sovateltide binds to endothelin-B receptors on endothelial cells in tumor blood vessels, which, unlike the angioarchitecture of normal blood vessels, are relatively devoid of smooth muscle.
Sovateltide
Not approved by the FDA. Being tested in clinical trials (furthest: Phase 4).
Only small or early studies in people so far.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Only small or early studies in people so far.
Not FDA-approved. In clinical trials (highest phase: Phase 4); 8 trial(s) listed on ClinicalTrials.gov, led by Pharmazz, Inc..
Last verified: Nov 11, 2026
Share your pre-launch perspective on Sovateltide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
